Signal Transduction and Targeted Therapy

Signal Transduction and Targeted Therapy (commonly abbreviated as ''Signal Transduct. Target. Ther.') is an open-access journal published by Springer Nature in partnership with West China Hospital of Sichuan University, China, carrying basic and translational work on signal transduction and the therapies that target it, and released through continuous online publication, reaching a 2025 impact factor of 81.2.Signal Transduction and Targeted Therapy（常用缩写 Signal Transduct. Target. Ther.）是由施普林格自然（Springer Nature）出版、与四川大学（中国）华西医院合作办刊的开放获取学术期刊，刊载信号转导及其靶向治疗的基础与转化研究成果，采用网络连续出版方式，2025 年影响因子达到 81.2。

Scope

The journal describes its mission as the timely publication of the latest discoveries and progress in both basic science and clinical research related to signal transduction and targeted therapy. It covers signal transduction in physiological and pathological processes, as well as signalling-pathway-targeted therapies in the form of biological agents and small molecular drugs used to treat human diseases.该刊的自我定位是及时发表信号转导与靶向治疗领域在基础科学和临床研究两方面的最新发现与进展，所收文章覆盖生理与病理过程中的信号转导，以及以生物制剂和小分子药物形式用于治疗人类疾病的信号通路靶向治疗。^[1]

• Basic and translational research: fundamental and translational work in molecular pharmacology and chemotherapy, drug sensitivity and resistance, and processes such as cell adhesion, invasion and metastasis, differentiation and cell death.基础与转化研究： 分子药理学与化学治疗学的基础及转化研究，药物敏感性与耐药性，以及细胞黏附、侵袭与转移、分化与细胞死亡等过程的研究。
• Tumour immunology and immunotherapy: tumour immunology and immunotherapy, together with the development and validation of biomarkers and prognostic indicators.肿瘤免疫与免疫治疗： 肿瘤免疫学与免疫治疗，以及生物标志物与预后指标的开发与验证。
• Gene and cell therapy: advances in gene therapy, and research into macromolecular biological agents, including cell therapies, and small molecular drugs directed at signalling pathways.基因治疗与细胞治疗： 基因治疗领域的进展，以及针对信号通路的各类大分子生物制剂（包括细胞治疗）与小分子药物的研究。
• Cross-disciplinary methods: systems biology, bioinformatics, pharmacy, medicinal chemistry, nanometre materials, computational chemistry and computational biology.跨学科方法： 系统生物学、生物信息学、药学、药物化学、纳米材料、计算化学与计算生物学等方法学方向。
• Disease scope: all major human diseases including cancer, immune disorders, diabetes, cardiovascular diseases, inflammation and central nervous system diseases, and the journal accepts original research articles, reviews, viewpoints and commentaries.疾病范围： 涵盖癌症、免疫性疾病、糖尿病、心血管疾病、炎症、神经系统疾病等各类主要人类疾病，既欢迎原创研究论文，也接受综述、观点与评论类稿件。

The journal is fully open access and charges no publication fees to authors, runs a fast-track route for original research, and positions itself as a leading forum for research on cell signal regulation, on molecular abnormalities that predict incidence and treatment response, on targeted drug discovery and preclinical studies, and on clinical trials of new therapies.刊物实行完全的开放获取出版，不向作者收取发表费用，采用快速评审通道以缩短原创成果的发表周期，其定位是成为细胞信号调控、可预测发病与疗效的分子异常、靶向药物发现以及新疗法临床试验领域的主要学术论坛。

History

• 2016: the journal was founded and began publication, launched through the partnership journals programme of Springer Nature, with its editorial office located at the State Key Laboratory of Biotherapy at West China Hospital of Sichuan University, China.2016年： 该刊于 2016 年正式创刊并开始出版，由施普林格自然旗下合作期刊平台推出，编辑办公室设在四川大学（中国）华西医院生物治疗国家重点实验室。
• Founding leadership: Carlo M. Croce, the Italian-born American cancer researcher then editor of Cancer Research and a member of the US National Academy of Sciences, served as a founding Editor-in-Chief and formed an international editorial team with two co-editors-in-chief.创刊主编： 意大利裔美国肿瘤学家卡洛·克罗切（Carlo M. Croce）出任创刊执行主编，他时任《Cancer Research》主编、美国国家科学院院士，与另两位共同主编一同组成了国际化编委团队。
• Change of leadership: David J. Kerr of the Radcliffe Department of Medicine at the University of Oxford, UK subsequently took over as co-Editor-in-Chief, succeeding Croce in that role.主编更替： 此后戴维·克尔（David J. Kerr）接任共同主编，该主编来自牛津大学（英国）拉德克利夫医学院，克罗切的共同主编职务随之结束。
• Open access and indexing: the journal was fully open access from the outset and levied no author fees, was subsequently indexed in SCIE, MEDLINE and the DOAJ, and saw its impact factor rise to 52.7 in 2024 before reaching 81.2 in 2025.开放获取与收录： 创刊时即全部开放获取并免收作者发表费用，随后被 SCIE、MEDLINE、DOAJ 等数据库收录，2024 年影响因子升至 52.7，2025 年进一步达到 81.2。
• Subject ranking: in JCR the journal ranks in the first quartile in both biochemistry and molecular biology and cell biology, and in the Chinese Academy of Sciences ranking it sits in the first tier of the medical sciences major and is flagged as a top journal.学科评价： 在 JCR 中列于生物化学与分子生物学和细胞生物学两个学科，均处于 Q1；在中国科学院期刊分区中位于医学大类 1 区并列为顶刊。

Editors

The journal has three co-Editors-in-Chief based at institutions in the UK, mainland China and China respectively, supported by Associate Editors and an Editorial Board of scholars from numerous countries, who handle review and acceptance decisions.该刊设三位共同主编分别来自英国、中国内地与中国的高等院校与研究机构，另设副主编、编委成员以及由全球多国学者组成的编辑团队，负责审稿与录用决策。

• David J. Kerr: professor at the Radcliffe Department of Medicine of the University of Oxford, UK, with a long-standing research record in chemotherapy and biomarkers for gastrointestinal cancers, and a current co-Editor-in-Chief of the journal.David J. Kerr： 牛津大学（英国）拉德克利夫医学院教授，长期研究消化道肿瘤的化疗与生物标志物，现任本刊共同主编。
• Kang Zhang: director of a centre for biomedicine and innovation at the Faculty of Medicine of the Macau University of Science and Technology, China, with extensive expertise in eye biology, stem cells and precision medicine, and a current co-Editor-in-Chief of the journal.Kang Zhang（张康）： 澳门科技大学（中国）医学院生物医学与创新中心主任，在眼科生物学、干细胞与精准医学领域有深厚积累，现任本刊共同主编。
• Yu-Quan Wei: head of the State Key Laboratory of Biotherapy and the clinical cancer centre at West China Hospital of Sichuan University, China, an academician of the Chinese Academy of Engineering, and a current co-Editor-in-Chief of the journal.Yu-Quan Wei（魏于全）： 四川大学（中国）华西医院生物治疗国家重点实验室与临床肿瘤中心负责人，中国工程院院士，现任本刊共同主编。
• Editorial board: the Associate Editors and Editorial Board members come from more than ten countries and regions including the United States, Australia, Germany, France, Italy and Japan, among them researchers at Princeton University, the University of Tokyo and the Massachusetts Institute of Technology. The full list appears on the journal's official website.编委构成： 副主编与编委成员来自美国、澳大利亚、德国、法国、意大利、日本等十余个国家与地区，其中不乏普林斯顿大学（美国）、东京大学（日本）与麻省理工学院（美国）等机构的学者，完整名单见期刊官网。^[2]